跳至主要内容
临床试验/NCT04209296
NCT04209296已完成不适用

A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of Excellence

Brain and Cognition Discovery Foundation1 个研究点 分布在 1 个国家目标入组 891 人开始时间: 2019年12月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
891
试验地点
1
主要终点
Quick Inventory of Depressive Symptomatology Self Report 16-Item

研究概览

简要总结

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.

研究设计

研究类型
Observational
观察模型
Ecologic Or Community
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Over the age of 18 years old. Patients over the age of 65 must receive additional approval to ensure safety.
  • Diagnosed with either MDD, BD, PTSD or OCD by a healthcare provider.
  • Experiencing an MDE as defined and operationalized in the DSM 5.
  • Individuals who may have comorbid psychiatric conditions, but the comorbid psychiatric condition can be neither the primary condition or the primary clinical concern.
  • Individuals reporting suicidal ideation will be included, as suicidal ideation is a symptom of MDE.
  • Individuals must have received at least 2 guideline concordant treatment trials with pharmacotherapeutic treatment options as suggested in the CANMAT MDD guidelines 2016, Florida Medicaid guidelines 2017, or the CANMAT ISBD guidelines for BD
  • Individuals who have received ECT or other neuromodulatory treatments will be eligible for ketamine infusion.

排除标准

  • Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
  • Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
  • Individuals who are unable to consent to the treatment.
  • Individuals who are unable to adhere to the protocol in its totality (i.e., remain in the clinic post infusion for up to 2-3 hours for observation).
  • Individuals who are unable to identify a person to assure their safe transport home following ketamine infusion.
  • Individuals with symptomatic traumatic brain injury.
  • Uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treated hypertension, allergies to ketamine and/or previous intolerability of ketamine).
  • Medical contraindications to ketamine.
  • Patients that are over 275 lbs

研究组 & 干预措施

Post-traumatic Stress Disorder (PTSD)

DSM-5 Diagnosis of PTSD

干预措施: Ketamine Hydrochloride (Drug)

Major Depressive Disorder (MDD)

DSM-5 Diagnosis of MDD

干预措施: Ketamine Hydrochloride (Drug)

Bipolar Disorder

DSM-5 Diagnosis of Bipolar Disorder

干预措施: Ketamine Hydrochloride (Drug)

Obsessive Compulsive Disorder (OCD)

DSM-5 Diagnosis of OCD

干预措施: Ketamine Hydrochloride (Drug)

结局指标

主要结局

Quick Inventory of Depressive Symptomatology Self Report 16-Item

时间窗: Over 4 inital infusions and maintance infusions (~2 years)

The QIDS-SR16 is a self-report assessment used to evaluate depression severity in patients with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, diagnosis of Major Depressive Episode. In total, there are 16 individual questions evaluating 9 DSM domains. The highest score is 27, indicating severe depression, while the lowest score is 0, which would suggest a complete absence of depressive symptoms.

Snaith-Hamilton Pleasure Scale

时间窗: Over 4 inital infusions and maintance infusions (~2 years)

The SHAPS assessment is a 14 item self report tool used to measure anhedonia. Each item can be have a response of 1 (Definitely agree), 2(Agree), 3(Disagree), and 4(definitely disagree). The total score ranges from 14 to 56, in which higher scores on the assessment indicate higher levels of anhedonia.

Sheehan Disability Scale

时间窗: Over 4 inital infusions and maintance infusions (~2 years)

The SDS contains 3 items, each ranging between zero to ten. The SDS is a self-reported assessment of disability within the context of depression. The total score ranges from 0, indicating no impairment, to 30, indicating severe impairment.

Generalized Anxiety Disorder 7-item

时间窗: Over 4 inital infusions and maintance infusions (~2 years)

The GAD-7 is a 7 item self-report assessment used to evaluate symptoms of anxiety. The scale ranges from 0 (not at all) to 3 (nearly every day). To total score ranges from 0 suggesting a lack anxiety symptoms to 21, indicating severe anxiety.

Endicott Work Productivity Scale

时间窗: Over 4 inital infusions and maintance infusions (~2 years)

The EWPS is a self report scale consisting of 25 items each ranging from 0 (high functioning) to 4 (low functioning). The total score ranges from 0 to 100, with 100 indicating extremely poor workplace productivity.

次要结局

  • Clinician Administered Dissociative States Scale(Over 4 inital infusions and maintance infusions (~2 years))

研究者

发起方
Brain and Cognition Discovery Foundation
申办方类型
Other
责任方
Principal Investigator
主要研究者

Roger McIntyre

Chairman and Executive Director

Brain and Cognition Discovery Foundation

研究点 (1)

Loading locations...

相似试验